Another bioactive component dihydrotanshinone I significantly inhibits the proliferation of ovarian cancer cells in vitro and in vivo by modulating the PI3K/AKT signaling pathway (Wang et al., 2020). This evidence concerns the gene AKT1 and ovarian carcinoma.